228 related articles for article (PubMed ID: 21864230)
1. The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics.
Widler L; Jahnke W; Green JR
Anticancer Agents Med Chem; 2012 Feb; 12(2):95-101. PubMed ID: 21864230
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
3. Nitrogen-containing bisphosphonates and cancer immunotherapy.
Clézardin P; Massaia M
Curr Pharm Des; 2010; 16(27):3007-2014. PubMed ID: 20722623
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
Ebetino FH; Sun S; Cherian P; Roshandel S; Neighbors JD; Hu E; Dunford JE; Sedghizadeh PP; McKenna CE; Srinivasan V; Boeckman RK; Russell RGG
Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
6. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
Dunford JE
Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.
Roelofs AJ; Thompson K; Ebetino FH; Rogers MJ; Coxon FP
Curr Pharm Des; 2010; 16(27):2950-60. PubMed ID: 20722616
[TBL] [Abstract][Full Text] [Related]
8. Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).
Endo Y; Kumamoto H; Nakamura M; Sugawara S; Takano-Yamamoto T; Sasaki K; Takahashi T
Biol Pharm Bull; 2017; 40(6):739-750. PubMed ID: 28566618
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid - a multiplicity of anti-cancer action.
Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
Russell RG; Watts NB; Ebetino FH; Rogers MJ
Osteoporos Int; 2008 Jun; 19(6):733-59. PubMed ID: 18214569
[TBL] [Abstract][Full Text] [Related]
12. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
13. Physiology of the aging bone and mechanisms of action of bisphosphonates.
Dominguez LJ; Di Bella G; Belvedere M; Barbagallo M
Biogerontology; 2011 Oct; 12(5):397-408. PubMed ID: 21695491
[TBL] [Abstract][Full Text] [Related]
14. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates: from bench to bedside.
Russell RG
Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
[TBL] [Abstract][Full Text] [Related]
16. [Introduction to bisphosphonates. History and functional mechanisms].
Fleisch H
Orthopade; 2007 Feb; 36(2):103-4, 106-9. PubMed ID: 17277961
[TBL] [Abstract][Full Text] [Related]
17. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
19. The backbone of progress--preclinical studies and innovations with zoledronic acid.
Green JR; Guenther A
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
[TBL] [Abstract][Full Text] [Related]
20. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Kavanagh KL; Guo K; Dunford JE; Wu X; Knapp S; Ebetino FH; Rogers MJ; Russell RG; Oppermann U
Proc Natl Acad Sci U S A; 2006 May; 103(20):7829-34. PubMed ID: 16684881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
